The Sentosa SQ Leukemia Panel is a DNA-based next generation sequencing (NGS)-based assay that identifies gene mutations including single-nucleotide variants (SNVs) and insertions and deletions (indels) on a single platform. The panel is designed to detect approximately 3,312 mutations in 49 key cancer genes.  The genes selected for this panel include targets associated with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and myeloproliferative neoplasms (MPN) as well as acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML), and chronic lymphocytic leukemia (CLL).

The highly automated Sentosa SQ NGS workflow with Sentosa SQ Leukemia Panel begins from the extraction of peripheral blood samples, to the generation of reports within 2.5 days .  This workflow requires less than 3.5 hours of hands-on time. 

For more information on the genes and target mutations, please contact authorized Vela Diagnostics representatives.

Supporting Decision-Making:

• Automated and user-friendly results interpretation with Sentosa SQ Reporter

Providing Laboratory Efficiency:

• From sample to result in 2.5 days
• Seamless sample traceability and IT connectivity